Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 6/20 | 0.49 |
| ▸ | FNTB | P49356 | 6/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739692 | 1.00 | LTA4H (0.56) | LTA4HMMEANPEPFNTAFNTB | |
| SCHEMBL4729126 | 1.00 | LTA4H (0.56) | LTA4HMMEANPEPFNTAFNTB | |
| SCHEMBL21239952 | 0.91 | LTA4H (0.53) | LTA4HMMEANPEPFNTAFNTB | |
| SCHEMBL21239953 | 0.91 | LTA4H (0.53) | LTA4HMMEANPEPFNTAFNTB | |
| SCHEMBL387497 | 0.90 | FNTA (0.56) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL29445856 | 0.90 | FNTA (0.56) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL387498 | 0.90 | FNTA (0.56) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL20558575 | 0.90 | FNTA (0.56) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL392068 | 0.90 | FNTA (0.56) | LTA4HFNTAFNTBPGGT1B | |
| SCHEMBL29445855 | 0.90 | FNTA (0.56) | LTA4HFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863467-A2 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006086456-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | claimed |
| WO-1992018159-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF NEPHROTOXICITY | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | claimed |
| EP-3943084-A1 | NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | Novartis AG (CH) | 2022-01-26 | — | — | EP | disclosed |
| EP-2887961-A1 | NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | Novartis AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029848-A1 | NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | NOVARTIS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| EP-1951309-A2 | COMBINATION OF AN ANGIOTENSIN II RECEPTOR BLOCKER, A CALCIUM CHANNEL BLOCKER AND ANOTHER ACTIVE AGENT | Novartis AG (CH) | 2008-08-06 | — | — | EP | disclosed |
| EP-1863467-A2 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007056324-A2 | COMBINATION OF AN ANGIOTENSIN II RECEPTOR BLOCKER, A CALCIUM CHANNEL BLOCKER AND ANOTHER ACTIVE AGENT | NOVARTIS AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006086456-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | disclosed |